Redsense Medical Spotlight presentation at the 61[st] ERA Congress in Stockholm
Redsense Medical will exhibit at the 61st ERA (European Renal Association) Congress in Stockholm, May 23-26, 2024. The Redsense blood loss security systems will be showcased at booth F.320, including the upcoming Clamp that is expected to be commercially launched during 2024.
The company was also allotted one of four Spotlight presentation slots, which is a novelty to this year’s programme and described as “Designed to showcase cutting-edge industry innovations and insights alongside scientific content”.
Redsense has invited high-profile hemodialysis physicians Dr. Christopher Chan from UHN Toronto, Canada, and Dr. Joachim Beige from KfH Kuratorium Leipzig, Germany, to present and lead discussion at the session titled “An examination of adverse vascular access bleeding events: solving the unmet gap”. The session will be held on Friday May 24 at 14:50 – 15:10 CEST on “the square” Spotlight Stage in the Exhibition area.
“It is an exceptional opportunity to have two physicians of this caliber presenting their data supporting the importance of improving safety in hemodialysis and doing so highlighting both the angle of instilling confidence in patients and as such empowering self-care, as well as underlying structural questions as reporting incidents, awareness and education, and reimbursement.” says Sebastien Bollue, COO of Redsense Medical leading Congress activities and Clamp evaluation.
The abstract of the presentation:
Venous needle dislodgment (or central venous catheter port disconnection) during hemodialysis sessions may lead to significant or even catastrophic blood loss, particularly during unsupervised therapies. Our symposium aims to illustrate the scope of this important safety concern and to provide a systematic review of the present mitigation strategies. Through iterative and usability design, the Redsense vascular access clamp device is developed with the aim to provide additional safety to dialysis without excessive intrusion. Through our presentations and interactive demonstration, we hope to address the aforementioned learning objectives. Our symposium is intended for all dialysis providers and stakeholders.
For more details about the presentation: https://era-apps.m-anage.com/era24/en-GB/pag/session/85558
For further information about the Congress: https://www.era-online.org/events/stockholm-2024/
“We look forward to participating in this premier event in the field of nephrology with visitors from all of the world. This Congress is an excellent opportunity for us to engage with stakeholders in the dialysis community and promote patient safety with the Redsense Alarm system and showcase our latest innovation, the Redsense Clamp, providing an extra layer of security for hemodialyis patients.” says Pontus Nobréus, CEO of Redsense Medical.
Contact information
For more information, please contact:
Pontus Nobréus, CEO
Telephone: +46 72-171 1264
E-mail: pontus.nobreus (at) redsensemedical.com
Redsense Medical AB (publ), 556646-4862
ABOUT REDSENSE MEDICAL
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS) and traded on OTCQX (RDSNF) in the US.